Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Medicare covers medically necessary treatment for eczema. This includes medicated creams and pills, dupilumab (Dupixent) injections, and phototherapy. Original Medicare with a Part D plan or an ...

Atopic dermatitis, also known as atopic eczema, is a long-term skin condition ... Sanofi to increase competition in atopic dermatitis market after Dupixent’s success - (https://www.globaldata ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Sales were also boosted by demand for the anti-inflammatory drug Dupixent, a treatment for eczema, asthma and, more recently, chronic obstructive pulmonary disease, among other indications.

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...